POPULARITY
Categories
340 episodes with Abstract
170 episodes with Abstract
91 episodes with Abstract
97 episodes with Abstract
72 episodes with Abstract
119 episodes with Abstract
72 episodes with Abstract
39 episodes with Abstract
57 episodes with Abstract
38 episodes with Abstract
40 episodes with Abstract
89 episodes with Abstract
28 episodes with Abstract
61 episodes with Abstract
15 episodes with Abstract
25 episodes with Abstract
20 episodes with Abstract
22 episodes with Abstract
25 episodes with Abstract
20 episodes with Abstract
13 episodes with Abstract
27 episodes with Abstract
31 episodes with Abstract
10 episodes with Abstract
14 episodes with Abstract
27 episodes with Abstract
30 episodes with Abstract
16 episodes with Abstract
12 episodes with Abstract
12 episodes with Abstract
17 episodes with Abstract
18 episodes with Abstract
19 episodes with Abstract
10 episodes with Abstract
10 episodes with Abstract
6 episodes with Abstract
12 episodes with Abstract
8 episodes with Abstract
8 episodes with Abstract
8 episodes with Abstract
33 episodes with Abstract
8 episodes with Abstract
7 episodes with Abstract
9 episodes with Abstract
5 episodes with Abstract
6 episodes with Abstract
44 episodes with Abstract
5 episodes with Abstract
7 episodes with Abstract
16 episodes with Abstract
8 episodes with Abstract
8 episodes with Abstract
16 episodes with Abstract
8 episodes with Abstract
4 episodes with Abstract
12 episodes with Abstract
12 episodes with Abstract
12 episodes with Abstract
6 episodes with Abstract
4 episodes with Abstract
13 episodes with Abstract
25 episodes with Abstract
5 episodes with Abstract
7 episodes with Abstract
19 episodes with Abstract
2 episodes with Abstract
5 episodes with Abstract
5 episodes with Abstract
2 episodes with Abstract
4 episodes with Abstract
99 episodes with Abstract
5 episodes with Abstract
9 episodes with Abstract
4 episodes with Abstract
10 episodes with Abstract
12 episodes with Abstract
4 episodes with Abstract
4 episodes with Abstract
8 episodes with Abstract
4 episodes with Abstract
20 episodes with Abstract
86 episodes with Abstract
4 episodes with Abstract
4 episodes with Abstract
8 episodes with Abstract
6 episodes with Abstract
7 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
3 episodes with Abstract
3 episodes with Abstract
15 episodes with Abstract
2 episodes with Abstract
5 episodes with Abstract
8 episodes with Abstract
5 episodes with Abstract
7 episodes with Abstract
4 episodes with Abstract
14 episodes with Abstract
2 episodes with Abstract
8 episodes with Abstract
3 episodes with Abstract
3 episodes with Abstract
6 episodes with Abstract
3 episodes with Abstract
7 episodes with Abstract
70 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
6 episodes with Abstract
4 episodes with Abstract
3 episodes with Abstract
7 episodes with Abstract
5 episodes with Abstract
3 episodes with Abstract
3 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
12 episodes with Abstract
8 episodes with Abstract
5 episodes with Abstract
4 episodes with Abstract
4 episodes with Abstract
6 episodes with Abstract
6 episodes with Abstract
2 episodes with Abstract
7 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
6 episodes with Abstract
3 episodes with Abstract
2 episodes with Abstract
6 episodes with Abstract
58 episodes with Abstract
3 episodes with Abstract
After thinking it was lost to the sands of internet time, our team uncovered a 2013 gem from the archives. In the “The Abstract Noun Edition,” your favorite Gabfesters talk about how we talk. Steve, Dana, and Julia discuss the elements of language: vocabulary, conversation, and voice. In paroxysms of polysyllables, they invoke their favorite writers—and their least favorite linguistic tics—to probe the best and worst of the English language. Why should you eschew the word “eschew”? What does “shibboleth” really mean? And where is the line between a strong voice and self-parody? Speaking of self-parody, check out these very on-brand 2013 Endorsements: Dana: The Sounding Joy, a CD collection of folk carols, collected by Smithsonian Folkways Recordings and performed by Elizabeth Mitchell. (Now available on streaming.) Julia: Creating an iTunes playlist of all songs you've played more than 10 times and then shuffling them. You'll rediscover old gems like “The Size of Our Love” by Sleater Kinney. Steve: The mind-bending “Monty Hall problem,” as originally described by Marilyn vos Savant in Parade Magazine. If you're in New York on January 5, don't miss some real life vocabulary, conversation, and voice when Steve joins Booker Prize-finalist Ben Markcovits for a conversation about The Rest of Our Lives — details here. Learn more about your ad choices. Visit megaphone.fm/adchoices
After thinking it was lost to the sands of internet time, our team uncovered a 2013 gem from the archives. In the “The Abstract Noun Edition,” your favorite Gabfesters talk about how we talk. Steve, Dana, and Julia discuss the elements of language: vocabulary, conversation, and voice. In paroxysms of polysyllables, they invoke their favorite writers—and their least favorite linguistic tics—to probe the best and worst of the English language. Why should you eschew the word “eschew”? What does “shibboleth” really mean? And where is the line between a strong voice and self-parody? Speaking of self-parody, check out these very on-brand 2013 Endorsements: Dana: The Sounding Joy, a CD collection of folk carols, collected by Smithsonian Folkways Recordings and performed by Elizabeth Mitchell. (Now available on streaming.) Julia: Creating an iTunes playlist of all songs you've played more than 10 times and then shuffling them. You'll rediscover old gems like “The Size of Our Love” by Sleater Kinney. Steve: The mind-bending “Monty Hall problem,” as originally described by Marilyn vos Savant in Parade Magazine. If you're in New York on January 5, don't miss some real life vocabulary, conversation, and voice when Steve joins Booker Prize-finalist Ben Markcovits for a conversation about The Rest of Our Lives — details here. Learn more about your ad choices. Visit megaphone.fm/adchoices
Charlie Uniman, your podcast host, and Pat Utz, CEO and co-founder of Abstract (https://www.abstract.us/), explore how Abstract turns legislative and regulatory noise into real-time, client-specific strategy, and why deterministic workflows beat agentic dreams for now. Pat shares candid lessons on funding, traction, hiring, and building a product that actually moves the needle.• origins in AI research and mission to make government transparent• proactive monitoring of bills, regulations, executive orders, and local agendas• real-time enrichment with client context to flag risks and opportunities• strategy layer and workflows that move from alert to outreach• planned expansion into judicial opinions to shape case law awareness• enterprise focus with long-term goal of a consumer version• founder advice on VC vs bootstrapping, traction before funding, and hiring fitIf you're interested in legal tech startups and enjoyed this podcast, please consider joining the free Legal Tech Startup Focus community by going to www.legaltech startupfocus.com and signing up
TL;DR LLMs pretrained on data about misaligned AIs themselves become less aligned. Luckily, pretraining LLMs with synthetic data about good AIs helps them become more aligned. These alignment priors persist through post-training, providing alignment-in-depth. We recommend labs pretrain for alignment, just as they do for capabilities. Website: alignmentpretraining.ai Us: geodesicresearch.org | x.com/geodesresearch Note: We are currently garnering feedback here before submitting to ICML. Any suggestions here or on our Google Doc are welcome! We will be releasing a revision on arXiv in the coming days. Folks who leave feedback will be added to the Acknowledgment section. Thank you! Abstract We pretrained a suite of 6.9B-parameter LLMs, varying only the content related to AI systems, and evaluated them for misalignment. When filtering the vast majority of the content related to AI, we see significant decreases in misalignment rates. The opposite was also true - synthetic positive AI data led to self-fulfilling alignment. While post-training decreased the effect size, benign fine-tuning[1] degrades the effects of post-training, models revert toward their midtraining misalignment rates. Models pretrained on realistic or artificial upsampled negative AI discourse become more misaligned with benign fine-tuning, while models pretrained on only positive AI discourse become more aligned. This [...] ---Outline:(00:15) TL;DR(01:10) Abstract(02:52) Background and Motivation(04:38) Methodology(04:41) Misalignment Evaluations(06:39) Synthetic AI Discourse Generation(07:57) Data Filtering(08:27) Training Setup(09:06) Post-Training(09:37) Results(09:41) Base Models: AI Discourse Causally Affects Alignment(10:50) Post-Training: Effects Persist(12:14) Tampering: Pretraining Provides Alignment-In-Depth(14:10) Additional Results(15:23) Discussion(15:26) Pretraining as Creating Good Alignment Priors(16:09) Curation Outperforms Naive Filtering(17:07) Alignment Pretraining(17:28) Limitations(18:16) Next Steps and Call for Feedback(19:18) Acknowledgements The original text contained 1 footnote which was omitted from this narration. --- First published: December 20th, 2025 Source: https://www.lesswrong.com/posts/TcfyGD2aKdZ7Rt3hk/alignment-pretraining-ai-discourse-causes-self-fulfilling --- Narrated by TYPE III AUDIO. ---Images from the article:
Abstract: The Christmas season evokes tender feelings within us as we contemplate the newborn Christ child, whose life and mission would change the world forever. Many retellings of the nativity story include the unusual—the awkward boy/innkeeper who impulsively offers his own room to Mary and Joseph or the Herdman kids who unwittingly impart a realistic view of the Christ child's birth. The Christmas star of Bethlehem, leading the wise men to the newborn baby, symbolically invites us to come unto Christ as we celebrate the season through memorable stories and Christmas songs. The post Christmas Stars: Inviting Us to Come to Christ first appeared on The Interpreter Foundation.
In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AMLAbstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapyAbstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CMLAbstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKIPresenter:Amir T. Fathi, MDDirector, Leukemia ProgramMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
El Dr. José Antonio de la Peña, hematólogo adscrito al Centro Médico Nacional “20 de Noviembre”, ISSSTE, en la Ciudad de México, México, nos comenta lo más destacado del Congreso Anual de la Sociedad Americana de Hematología 2025.Síndrome mielodisplásico y leucemia mieloide agudaEstudio retrospectivo multicéntrico que evaluó el impacto de añadir venetoclax a agentes hipometilantes como tratamiento de primera línea en pacientes con síndrome mielodisplásico de riesgo intermedio-alto a muy alto, según el sistema internacional de puntuación pronóstica revisado. (1)Estudio retrospectivo que evaluó el valor pronóstico de la duración de la respuesta completa en pacientes con síndrome mielodisplásico de alto riesgo tratados con azacitidina. Se incluyeron pacientes que alcanzaron respuesta según criterios IWG 2006/2022, definiéndose respuesta completa duradera como aquella con una duración ≥ 6 meses. (2)El mantenimiento tras el trasplante de médula ósea en leucemia mieloide aguda debe considerarse de forma amplia, idealmente en todos los pacientes, incluso antes de contar con un análisis molecular completo. Existen terapias dirigidas disponibles para alteraciones específicas como FLT3 e IDH, que permiten estrategias de mantenimiento personalizadas. (3)PARADIGM fue un ensayo fase II, abierto, multicéntrico y aleatorizado, que comparó azacitidina + venetoclax frente a quimioterapia intensiva estándar (7+3) como tratamiento de primera línea en pacientes con leucemia mieloide aguda sin factores de alto riesgo. (4) Referencias:Murthy GSG, Ball S, Feld J, Abboud R, Haddadin M, Patel SA, Kishtagari A, Hawkins H, Guerra V, Dworkin E, et al. Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome: impact of subgroups on clinical outcomes. Blood. 2025. Abstract presented at the American Society of Hematology Annual Meeting.Braisch TF, Sallman DA, Komrokji RS, et al. Durability of complete response is a stronger predictor of overall survival than complete response rate in patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2025. Abstract presented at the American Society of Hematology Annual Meeting.Levis MJ. Maintenance therapy after allogeneic stem cell transplantation for acute myeloid leukemia: who, when, why, and how long? Blood. 2023;141(9):1001–1010. https://doi.org/10.1182/blood.2022019287.Fathi AT, Uy GL, Montesinos P, et al. Azacitidine plus venetoclax versus intensive chemotherapy as frontline therapy for patients with newly diagnosed acute myeloid leukemia: results from the randomized phase II PARADIGM study. Blood. 2024;144(Suppl 1). Abstract presented at the American Society of Hematology Annual Meeting.
Humanity has talked about aliens throughout recorded history, and obsession that has changed science, faith, and media. The past few years have been very exciting for those who want to believe. The U.S. government has released tantalizing videos and held several gripping hearings showing and discussing UFOs. People who always thought the government was hiding evidence of alien life from the general population saw it as proof that what they've said was happening all along. Skeptics have made compelling arguments for why all these revelations could be anything but aliens. But this debate and humanity's obsession with aliens goes as far back as recorded history. In her book, First Contact: The Story of Our Obsession with Aliens, 404 Media's science reporter and author of The Abstract newsletter Becky Ferreira delves deep into this history, what it teaches us about humans, and what the near and far future of the search for alien life looks like. I had a great time reading Becky's book and an even better time discussing it with her on the podcast. It's a great conversation that unpacks why these stories get so much attention, and a perspective on aliens in the news and pop culture that's rooted in history and science. YouTube Version: https://youtu.be/QToByEeq2vU Subscribe at 404media.co for bonus content. Learn more about your ad choices. Visit megaphone.fm/adchoices
Becky Ferreira is a science writer whose work has appeared in The New York Times, Motherboard/VICE, WIRED, Popular Science, MIT Technology Review, and The Washington Post, among other publications. She's also been an expert guest on the Science Channel and writes the Abstract column for 404 Media. She has written the book FIRST CONTACT: The Story of Our Obsession with Aliens, which takes a science based approach to life beyond our planet. https://www.beckyferreira.com Purchase the book here: https://www.hachettebookgroup.com/titles/becky-ferreira/first-contact/9781523527755/ Learn more about your ad choices. Visit podcastchoices.com/adchoices
This is the abstract and introduction of our new paper. Links:
This deep dive comprehensively challenges the foundational materialist model by synthesizing cutting-edge biological research with decades of high-strangeness data, including near-death experiences (NDEs), the UAP phenomenon, and reports of paranormal events. The central conflict addressed is whether reality consists of separate physical things or is fundamentally an expression of a unified, non-local field, leading to the essential question of whether physical matter creates consciousness or is merely its byproduct.The sources argue that science, while possessing immensely powerful models capable of precise description (how gravity or cells work), fundamentally fails to provide the ultimate explanation (why these laws exist), creating a "total black box". This distinction between description and explanation highlights the historical hubris seen in the late 19th century, when influential physicists believed "everything had already been discovered," only for Relativity and Quantum Mechanics to shatter the perceived fixed laws of reality soon after. This failure of explanation persists today, making highly descriptive data, such as military UAP reports, intractable because the required underlying theory of existence is missing.The inadequacy of the materialist view forces a paradigm shift to reality defined by non-physical information and pattern, termed the Platonic blueprint. Abstract truths, such as the constant π or the Fibonacci sequence, are discovered, not invented, and exist as fixed, immutable relationships independent of physical matter. This suggests they are the "deep architecture" or scaffolding upon which the physical universe is built.Physical matter is reduced to an "epiphenomenon"—a secondary effect or byproduct, like smoke from the fire that is the primary field.The brain is thus viewed not as the source of consciousness, but as a "localized receiver" or terminal jacked into a non-local network. Consciousness must be the operating system itself, given that cognitive scientists view spacetime as merely an interface or "headset" designed for survival, meaning the brain, which exists inside that construct, cannot possibly create consciousness. This concept of consciousness as a non-local field is overwhelmingly validated by experiential data from NDEs, where survivors often report a sense of oneness and intuitive, expansive knowledge that cannot be explained by the local brain, such as a blind woman suddenly understanding calculus.Dr. Michael Levin's work aligns with this pattern-based view, focusing on agency and goal-seeking capacity regardless of material composition. He defines the self by the scale of its goals—its "cognitive light cone". Disease, like cancer, is reinterpreted as a failure of collective cognition where cells shrink their light cone and revert to a primitive, selfish imperative. Experimental systems like xenobots, which are simple cells demonstrating sophisticated, complex competencies like kinematic self-replication without any evolutionary history for the behavior, strongly suggest that the patterns for these minds are pulled from a pre-existing latent space, the Platonic field.Ultimately, the sources conclude that reality is a participatory universe, where observation shapes outcomes and the distinction between the observer and the observed is dissolved. The UAP phenomenon exemplifies this by its "highly reflexive" nature, mirroring the witness's culture, trauma, or expectation. This deliberate ambiguity—the phenomenon persistently staying "just out of reach"—is crucial, as it forces humanity to constantly upgrade its understanding of reality, ensuring that the game of discovery and developmental growth continues. #NonLocal #cancercure #PlatonicBlueprint,.#ConsciousnessIsFundamental #ParticipatoryUniverse #PostMaterialism #MichaelLevin #CognitiveAgency #Brain #UAPPhenomenon #Xenobots #REALITY #HighStrangeness #BigBang
“Middle school kids really are very concrete learners. Abstract thought isn't there yet. Give them the ability to see ‘I'm not the only one having problems on page 10. I must be normal because everybody's having problems on page 10.' Or, if it is a kid who's the only one who's having a problem, let's figure out what the problem is. Let the kids have some voice in helping problem-solve rehearsal issues. The teacher is the expert, but that doesn't mean that you know everything. Sometimes a kid knows a lot of stuff, but it is just sounds different or is coming from a different angle.”Gretchen Harrison, National ACDA Chairperson for Repertoire and Resources, is a Missouri-born, Kansas-educated, veteran choral educator, conductor and clinician.. Proud to come from a strong choral music heritage, Harrison is the middle generation of a 3-generation ACDA family. She follows in her dad's footsteps as “teacher-mentor” with joy! She loves a rehearsal based on love, excellence, urgency, laughter, respect, high expectations, silliness and, hopefully, dark chocolate! Harrison has served ACDA as State Chair for JHMS Repertoire and Standards (KS), as the National Chair for JHMS Repertoire and Standards, then Resources, as the first Youth Choirs Coordinator and, now, as the National Chair. Harrison earned degrees from Wichita State University (BME) and the University of Missouri–Kansas City (MME) and has 60+ additional hours of study. Professionally, Harrison retired after teaching public school middle school choir for 34 years. She is the 2023 recipient of the “Harry Robert Wilson Award”, an award by the Kansas ACDA chapter to recognize lifelong achievement. She is the administrator in the Allegro Choirs of Kansas City community choir program. Harrison is married to a retired band director and mom to two wonderful humans and “Gigi” to a wonderful grandson–with another on the way. She loves her family, cooking, baking, her dog and reading.To get in touch with Gretchen, you can email her at nationalrr@acda.org, follow the ACDA Repertoire Collective Facebook page (@RepertoireResources), or find her on Facebook (@gretchen.harrison) or Instagram (@gretchenharrison).Email choirfampodcast@gmail.com to contact our hosts.Podcast music from Podcast.coPhoto in episode artwork by Trace Hudson
How cool is this Iris? I love getting up close to flowers to see all the crazy details you usually miss. This bearded iris has these intense, deep burgundy petals Continue Reading Read more on this topic: Gifts: A bee gathering on purple coneflower Products from Douglas E. Welch Design and Photography [Shopping] New Design: Trichocereus Cactus Flower Products [Shopping] New Design: Garden View, Theodore Payne Foundation, Sun Valley, California [Merch] New Design: Vintage Blue Passion-flower Prints and other products [Shopping] Daffodil Closeup via Instagram [Photography]
How cool is this Iris? I love getting up close to flowers to see all the crazy details you usually miss. This bearded iris has these intense, deep burgundy petals with super intricate white and violet veining. But the best part is definitely that fuzzy, golden-yellow “beard” right in the center—it almost glows! The soft, blurred background makes the flower really pop. It's a moody, dramatic, and beautiful piece of nature that’s perfect if you love unique florals that make a statement ORDER TODAY Also available on throw blankets, pillows, tops, tees, iPhone cases, and much more! *Redbubble has discounts when purchasing multiple items and also gives 10%-20% discounts on a regular basis. Check back often! See More Products On These Sites DouglasEWelch.com/shop/follow | PixelFed | Bluesky | Mastodon | Threads See my entire catalog DouglasEWelch.com/shop/
Politically Entertaining with Evolving Randomness (PEER) by EllusionEmpire
Send us a textWe explore how AI and open data can shift healthcare from reactive to proactive, cutting waste and improving outcomes without replacing clinicians. We also compare Brazil and the US, unpack the economics of chronic disease, and touch on regulation, fraud, and the future of molecular diagnostics.• AI as augmentation to prioritize scarce clinician time• Brazil–US parallels in private care and funding constraints• Transition from acute to chronic care models with monitoring• Diabetes cost breakdown and avoidable complications• Targeting the highest-risk 5 percent for early intervention• Fighting fraud and administrative waste with pattern detection• Regulation, human oversight, and feedback loops for safety• Molecular biology and biomarkers for earlier prediction• Genetics versus lifestyle in personalized care planning• Art, abstraction, and AI as creative tools beyond clinicsFollow Mariano Garcia-Valino at ...His website that has huge artwork collectionhttps://mgarciavalino.com/LinkedInhttps://www.linkedin.com/in/mgarciavalino/Support the showFollow your host atYouTube and Rumble for video contenthttps://www.youtube.com/channel/UCUxk1oJBVw-IAZTqChH70aghttps://rumble.com/c/c-4236474Facebook to receive updateshttps://www.facebook.com/EliasEllusion/ LinkedIn https://www.linkedin.com/in/eliasmarty/ Some free goodies Free website to help you and me https://thefreewebsiteguys.com/?js=15632463 New Paper https://thenewpaper.co/refer?r=srom1o9c4gl PodMatch https://podmatch.com/?ref=1626371560148x762843240939879000
Abstract: One of the most notable features of Nephi's small plates rendition of Isaiah chapter 2 (2 Nephi 12) is the prominent expansion of the nations theme with two additional clauses with the word nations (Hebrew gôyim) that are not found in the Masoretic text (from which the KJV has been translated). Nephi's text preserves the use of nations from Isaiah 2:2, 4 in 2 Nephi 12:2, 4, but also attests significant additional references to the nations in 2 Nephi 12:12, 14: “For the day of the Lord of Hosts soon cometh upon all nations, yea, upon every one . . . and upon all the nations which are lifted up, and upon every people.” These variants are consistent with—and may even be explained by—Nephi's declaration of intent in 2 Nephi 25:3: “Wherefore, I write unto my people, unto all those that shall receive hereafter these things, which I write, that they may know the judgments of God, that they come upon all nations, according to the word which he hath spoken” (2 Nephi 25:3). This purpose in writing might explain additional textual variants in 2 Nephi 12–24 that pertain to coming judgments upon the nations, which is a dominant theme of the writings of Isaiah, which Nephi incorporated into this part of his record. The post “Upon All the Nations”: The gôyim in Nephi's Rendition of Isaiah 2 (2 Nephi 12) in Literary Context first appeared on The Interpreter Foundation.
In this episode, we showcase student research at the 2025 ADSA Annual Meeting in Louisville, Kentucky. Abstracts can be found here: ADSA 2025 Annual MeetingAbstract 2186: Effects of feeding alternative forage silages on early lactation performance and gas production in multiparous Holstein cows. (00:15)Guests: Barbara Dittrich and Dr. Heather White, University of Wisconsin-MadisonCo-Host: Dr. Clay Zimmerman, BalchemBarbara substituted rye silage, triticale silage, rye-camelina-hairy vetch silage, and triticale-camalina-hairy vetch silage to replace 10% of the alfalfa silage in the control diet for her experimental diets. Dry matter intake and gas production were similar across diets. Average milk yield was higher in the rye mix silage group compared to the triticale mix silage group, but no treatment was different than the control. Abstract 1602: Optimizing starch concentrations in low-forage diets. (11:22)Guests: Irie Moussiaux and Dr. Kirby Krogstad, Ohio State UniversityCo-host: Dr. Jeff Elliott, BalchemIrie investigated different levels of starch in a low-forage diet (12.5% NDF) by replacing soybean hulls with corn to yield 20%, 25%, or 30% starch. Dry matter intake and milk production were the same for all three starch concentrations; however, the low starch diet had the highest milk fat yield and energy-corrected milk yield. Abstract 2183: Effects of partial replacement of corn and oat silages with extracted stevia plant on production, behavior, and digestibility in dairy cows. (17:05)Guests: Mariana Marino and Dr. Jose Santos, University of FloridaCo-host: Dr. Clay Zimmerman, BalchemMariana fed stevia plant byproduct as a replacement for corn and oat silage in lactating cow diets. All diets had 40% grain and 60% forage. Stevia byproduct was included at 0, 25%, or 40% of diet dry matter. The byproduct is of very fine particle size and is relatively high in lignin. This resulted in higher dry matter intake, but lower milk production for the highest stevia diet. Abstract 2472: Evaluating feed sorting behavior and TMR composition in roughage intake control feeding systems. (26:38)Guests: Sophia Green and Dr. Heather White, University of Wisconsin-MadisonCo-host: Dr. Ryan Pralle, BalchemSophia evaluated feed sorting in a research intake control feeding system (RIC bins). Feed sorting primarily occurred in the last 12 hours of the feed day, and particle size was smaller at the end of the day than earlier. Compared to fresh feed at hour zero, the chemical composition of the diet did not change throughout the feed day. RIC bins did not introduce additional variance in nutrient consumption. Abstract 1603: Assessing an ex vivo assay with gastrointestinal tissue sections to investigate mucosal immune responses in dairy calves. (35:24)Guests: Paiton McDonald and Dr. Barry Bradford, Michigan State UniversityPaiton challenged explants from the ileum and mid-jejunum in the lab with rotavirus or E. coli compared to a control. Pathogen stimulation increased mRNA abundance of TNF and IL6 above control. Ileal sections secreted more cytokines than jejunal sections. Abstract 1466: The short-term effect of increasing doses of palmitic and stearic acid on plasma fatty acid concentration and mammary arteriovenous difference in Holstein cows. (40:17)Guests: Alanna Staffin and Dr. Kevin Harvatine, Penn State UniversityCo-host: Dr. Jeff Elliott, BalchemAlanna fed mid-lactation cows 0, 150, 300, 500, or 750 grams of palmitic acid, stearic acid, or no supplement control. Palmitic acid increased milk fat yield at lower doses compared to stearic acid. Alanna found that the mammary gland increases its arteriovenous (AV) difference and uptake of palmitic acid when higher concentrations are provided, but AV difference and uptake of stearic acid did not change. Abstract 2006: Does hay improve performance in pair-housed dairy calves? (50:00)Guests: Gillian Plaugher and Dr. Melissa Cantor, Penn State UniversityGillian fed pelleted hay to pair-housed dairy calves along with milk replacer and calf starter. Control calves received milk replacer and calf starter only. Hay-fed pairs grew faster than controls after day 21 and were heavier at day 70. Hay feeding did not impact calf starter DMI or feed efficiency. Abstract 1463: Dietary metabolizable protein and palmitic and oleic acids affect milk production in early lactation dairy cows. (1:02:03)Guests: Jair Parales-Giron and Dr. Adam Lock, Michigan State UniversityCo-host: Dr. Clay ZimmermanJair fed two different levels of metabolizable protein and 3 different levels of supplemental fatty acids from 1 to 22 days in milk followed by a common diet to evaluate carryover effects to day 50. Metabolizable protein and fatty acid supplementation had additive effects on milk production. Cows fed the highest dose of both metabolizable protein and fatty acids produced 8.9 kg more energy-corrected milk per day compared to the low metabolizable protein diet without fatty acid supplementation.
Abstract: Taylor Petrey's Queering Kinship in the Mormon Cosmos attempts to “queer” Latter-day Saint concepts to create an account more congenial to queer theory, a postmodern philosophy and approach to texts. Here the aim is to destabilize and deny sexual essentialism, the law of chastity, and the eternal destiny of humanity as understood by the Saints. The words of Church leaders are misrepresented through omission and reorganization. Readings of Latter-day Saint scholars and scripture likewise suffer distortion and inaccurate representation. The work betrays several double standards, including the intellectual colonialism inherent in the efforts to distort and thereby appropriate Latter-day Saint culture and writings for its own purposes. Means to avoid this negative pattern are suggested, including rigorous honesty in textual claims and the participation of the scholarly community in effective peer review of irresponsible or misleading work. The post Intellectual Colonialism and Air Bud Theology: More on Queer Theory and the Church of Jesus Christ first appeared on The Interpreter Foundation.
This week, Amy and Matt get into the Jake-centric episode, "Abstract", then we gun it over to "Ketchup", which is a pretty cool spin on the typical flashback episode. Then we talk about the final Fionna and Cake episode from the original Adventure Time series, "Fionna and Cake and Fionna"!Also, stick around for a special announcement at the end!Rate us on Apple Podcasts! itunes.apple.com/us/podcast/oh-my-glob-an-adventure-time-podcast/id1434343477?mt=2Contact us: ohmyglobpodcast@gmail.comInstagram: @ohmyglobpodTrivia Theme by Adrian C.
To get live links to the music we play and resources we offer, visit www.WOSPodcast.comThis show includes the following songs:Claudia Hoyser - Tides Gonna Rise FOLLOW ON SPOTIFYLyn Bowtell - Scene Of The Crime FOLLOW ON SPOTIFYVanilla Abstract - I Was Happy FOLLOW ON SPOTIFYAllison Park - Pushing Bruises FOLLOW ON SPOTIFYSteph Maguire - Drinkin (one more time) FOLLOW ON SPOTIFYEmma Grace Glover - Secrets Are Safe FOLLOW ON SPOTIFYKate Swan - Hometown FOLLOW ON SPOTIFYSara Hynson - Another Man Like You FOLLOW ON SPOTIFYKylanne - Force of Nature FOLLOW ON SPOTIFYAudrey Claire - Apart FOLLOW ON SPOTIFYMeera Blackburn - Better Days FOLLOW ON SPOTIFYSophie Lane - Time FOLLOW ON BANDCAMPKirsten Agresta Copely - Intertwined FOLLOW ON SOUNDCLOUDAylee - Slow Down FOLLOW ON SPOTIFYLuna Scott Russell - Let's Get Together FOLLOW ON SPOTIFYFor Music Biz Resources Visit www.FEMusician.com and www.ProfitableMusician.comVisit our Sponsor Profitable Musician Newsletter at profitablemusician.com/joinVisit our Sponsor Bandzoogle at: http://www.bandzoogle.comVisit our Sponsor Mairose at https://linktr.ee/mairose26Visit our Sponsor 39 Sources of Income at profitablemusician.com/incomeVisit www.wosradio.com for more details and to submit music to our review board for consideration.Visit our resources for Indie Artists: https://www.wosradio.com/resourcesBecome more Profitable in just 3 minutes per day. http://profitablemusician.com/join
The Rocktober 2025 New Music Train sets off for its journey with the listeners today, leaving Scotland and heading for Illinois for a ride with Steven Routledge and Paul Hayden. They will give you the lowdown on new tunes from An Abstract Illusion, Friendship Commanders, Guided By Voices and Belair Lip Bombs. Rockin' the Suburbs on Apple Podcasts/iTunes or other podcast platforms, including audioBoom, Spotify, Google Podcasts, Amazon, iHeart, Stitcher and TuneIn. Or listen at SuburbsPod.com. Please rate/review the show on Apple Podcasts and share it with your friends. Visit our website at SuburbsPod.com Email Jim & Patrick at rock@suburbspod.com Follow us on the Threads, Facebook or Instagram @suburbspod If you're glad or sad or high, call the Suburban Party Line — 612-440-1984. Theme music: "Ascension," originally by Quartjar, next covered by Frank Muffin and now re-done in a high-voltage version by Quartjar again! Visit quartjar.bandcamp.com and frankmuffin.bandcamp.com.
Listen to the Education Research Oral Abstracts presented live at EMS Expo.
Send us a textIn this insightful conversation, we explore the question: Is myopia truly a disease? Join us as Mark Bullimore sheds light on the intricate nuances of this visual condition and its impact on our overall eye health.Discover the significance of each diopter and gain a deeper understanding of why it matters. About Mark Bullimore:Professor Bullimore is an internationally renowned scientist, speaker, and educator based in Boulder, Colorado. He received his Optometry degree and PhD in Vision Science from Aston University in Birmingham, England. He spent most of his career at the Ohio State University and the University of California at Berkeley and is now Adjunct Professor at the University of Houston. He is Associate Editor of Ophthalmic and Physiological Optics and the former Editor of Optometry and Vision Science. His expertise in myopia, contact lenses, low vision, presbyopia, and refractive surgery means that he is consultant for a number of ophthalmic, surgical, and pharmaceutical companies. This work has resulted in approval of, among others, Paragon CRT, Alcon's iLux, and CooperVision's MiSight lens.Resources Mentioned:Myopia Calculator linkhttps://bhvi.org/myopia-calculator-resources/Why every diopter mattershttps://journals.lww.com/optvissci/Abstract/2019/06000/Myopia_Control__Why_Each_Diopter_Matters.11.aspxThe Risks and Benefits of Myopia Controlhttps://www.aaojournal.org/article/S0161-6420(21)00326-2/fulltext
Review of Lincoln H. Blumell, Lady Eclecte: The Lost Woman of the New Testament (Minneapolis, MN: Fortress Press, 2025). 314 pages. $48.00 (hardcover). Abstract: For centuries, the consensus reading of 2 John 1 maintained that the epistle was written to a local church, metaphorically addressed as an “elect lady.” This has most especially been the case over the last 150 years of scholarship. However, new findings from Lincoln Blumell challenge the consensus reading, restoring the elect lady to her proper place as an actual individual in the early Christian world. This lady, moreover, can be identified by name, and it is only through haplography that confusion over her identity has been introduced at all. Blumell's restoration of the text of 2 John 1, based on papyrological and manuscript evidence, is groundbreaking work that will shape scholarship on the New Testament and early Christianity for years to come. The post Finding the Elect Lady first appeared on The Interpreter Foundation.
Matters Microbial #116: Microbes in the Concrete Instead of the Abstract November 14, 2025 Today Dr. Julie Maresca, Associate Professor in the Department of Chemistry at the SUNY College of Environmental Science and Forestry joins the #QualityQuorum to discuss how bacteria can interact with a ubiquitous part of modern life: concrete! Host: Mark O. Martin Guest: Julie Maresca Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode Hartiful, the vendor that makes the enamel pins I often show on the podcast. An overview of microbes and the "built environment." An article about how concrete is made. A video on how concrete is made. The concept of "self repairing" concrete. An overview of the microbial limits to life with regard to pH. A description of alkalinophilic bacteria. Biofilms that form on concrete. Difficulties in obtaining DNA from rock. An overview of oligotrophic microbes. The alkali-silica reaction in concrete. Challenges of road salt and concrete. An overview of halophilic microbes. An overview of xerophilic microbes. The concept of SLiME communities. The term aeonophiles. Is "Roman" concrete self-repairing? A company that produces "microbial concrete." An article relevant to today's discussion by Dr. Maresca and colleagues. Dr. Maresca's faculty website. Dr. Maresca's wonderful and artistic research website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com
Ayelet Fishbach, motivation researcher at University of Chicago, dismantles the fantasy-driven approach to New Year's resolutions and goal-setting. Drawing from data spanning multiple years, she reveals that while temporal landmarks like New Year work for initiating goals, only 20% of people still pursue them by November—the difference comes down to whether you're fantasizing or planning. Fishbach explains how fantasies (envisioning yourself already achieving the goal) actually decrease motivation to send job applications or take action, whereas concrete plans ("I will call my connections, work on my resume, here are the steps") drive execution. She introduces the critical balance between "why" questions (abstract purpose that prevents you from giving up) and "how" questions (concrete steps that enable execution), warning that goals become too abstract when they reach "I want to be happy" and too concrete when you lose sight of why you're doing them. The conversation explores Michael Phelps' visualization strategy (preparing for goggles filling with water, not just winning gold) and why optimism without planning is just delusional fantasy masquerading as motivation. Hosted on Acast. See acast.com/privacy for more information.
This week on the Art Problems podcast interview series “Inside Netvvrk”, I'm talking with Ann Marie Auricchio, an abstract painter who creates work at the intersection of psychological and physical experiences. Ann Marie shares what it's like to restart your art career after 25 years in another profession. She talks about why having all your materials ready isn't enough if you don't know how to use them, and how a shoulder injury became the perfect time to invest in herself. We get into how she went from feeling stuck and isolated in New Orleans to landing her first museum solo show and working with multiple galleries. She also explains how writing exhibition proposals with other Netvvrk members led to actual acceptances—and taught her when to turn down opportunities that don't financially make sense. We also talk about researching institutions by looking at other artists' CVs and why community matters even when people can be annoying. If you're restarting your career or feeling isolated in your practice, this conversation will help. It shows what's possible when you get your assets in order and find your people.
Featuring an interview with Dr Aaron Lisberg, including the following topics: Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;33(9):756. Abstract Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;[Online ahead of print]. Abstract Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract Novel Strategies Combining Dato-DXd with Osimertinib (10:44) Lu S et al. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). ASCO 2025;Abstract TPS8647. Nadal E et al. TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. ELCC 2025;Abstract 124TiP. Intracranial Activity Observed with TROP2-Targeting Antibody-Drug Conjugates (15:14) Felip E et al. Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial. ELCC 2025;Abstract 13P. Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593. Pons-Tostivint E et al. Intracranial efficacy of datopotamab deruxtecan (Dato- DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. WCLC 2025;Abstract OA10.01. CME information and select publications
Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT Southwestern Medical Center; and Udhayvir S. Grewal, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Each doctor focused on a specific disease type, highlighting the most important abstracts in colorectal cancer, pancreatic neuroendocrine tumors (NETs), and upper gastrointestinal cancers. The Phase 3 MATTERHORN Trial (NCT04592913) Results from MATTERHORN demonstrated that adding durvalumab (Imfinzi) to 5-fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel (FLOT) improved overall survival (OS) compared with FLOT plus placebo in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, regardless of pathological status.1 In the intention-to-treat population, the median OS was not reached in either arm, and the hazard ratio (HR) was 0.78 (95% CI, 0.63-0.96; P = .021). Notably, the improvement was observed regardless of PD-L1 status; in patients with PD-L1–positive disease, the HR was 0.79 (95% CI, 0.63-0.99), and in patients with PD-L1–negative disease, the HR was 0.79 (95% CI, 0.41-1.50). “This, I believe, will seal durvalumab plus FLOT as the standard of care for resectable [gastric/GEJ] cancers,” said Brown. The Observational ASPEN Study (NCT03084770) The ASPEN study showed that active surveillance was a safe approach for patients with low-grade, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NETs) fewer than 2 centimeters in size.2 Of the 1000 patients enrolled in the trial, 20 patients died, of whom 18 underwent active surveillance and 2 underwent surgery. Nineteen of the deaths were unrelated to pancreatic NETs; 1 death in the surgery arm was related to a pancreatic NET. After surgery, 5 patients had disease relapse or progression. With a median follow-up of 42 months (IQR, 25-60), the OS analysis showed a P value of 0.530. “This really settles the debate on whether or not to surgically operate on patients with a [pancreatic NET] size of [fewer] than 2 centimeters and shows that active surveillance is a safe option for these patients with pancreatic NETs [fewer] than 2 centimeters in size and non-functional NETs,” said Grewal. Data From the Phase 2/3 FOxTROT (NCT00647530) and Phase 2 NICHE-2 (NCT03026140) Trials Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) achieved a clinically meaningful and statistically significant improvement in long-term outcomes, including responses and survival, compared with chemotherapy strategies in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced colon cancer.3 In NICHE-2, neoadjuvant nivolumab plus ipilimumab achieved a 3-year disease-free survival (DFS) rate of 100% compared with 80% (95% CI, 73%-85%) with all chemotherapy strategies in FOxTROT (P
Abstract: The Restoration of the Gospel began in an atmosphere of ardent and urgent expectations of the Second Coming of Christ. We are, after all, The Church of Jesus Christ of Latter-day Saints. Those expectations were shared far beyond the ranks of those who eventually joined the Church. But the early nineteenth-century men and women who did become Latter-day Saints were commanded that, having been warned, they should warn their neighbors. However, nearly two full centuries since the founding of the Church, and more than two centuries since Joseph Smith's First Vision, the Lord's Second Advent has still not arrived. Does that mean that this isn't a time for warning? That the time to warn our neighbors hasn't yet come? No, not at all. We remain under the divinely given obligation to spread the word and, yes, to warn. And there are many ways to do so. The post “A Voice of Warning” first appeared on The Interpreter Foundation.
Is fertility preservation worth it for women over the age of 35? In this episode of Fertility Forward, we welcome Dr. Michelle Bayefsky to discuss her ASRM Abstract, ‘Outcomes for Patients Who Underwent Oocyte Cryopreservation at Age 35 Years and Older: Results from a Large, Multi-Centre Cohort'. Tuning in, you'll hear about the study, who was involved, what she discovered from it, and how she hopes to further her studies on fertility preservation in women over 35 in the future. We even touch on the power and importance of providing patients with data so they can make decisions for themselves. Finally, and as always, we share what we are grateful for today. Thanks for listening!
in abstract things or be derided by - #4336 (95R70 percent 200 left) by chair house 251028.mp3in abstract things or be derided by◆《ピアノ万葉集》セレクションアルバムの第３１アルバムが完成して、世界中の音楽配信サイトから配信が始まりました。最近は海外からの視聴頂く方も増えていて嬉しい限りです。このアルバムの１曲目はちょっと好きな音楽なので是非聴いて..
JPYC yen-backed stablecoin goes live on Ethereum. Abstract enables 200ms block times. And ETHZilla sells $40 million worth of ETH. Read more: https://ethdaily.io/811 Disclaimer: Content is for informational purposes only, not endorsement or investment advice. The accuracy of information is not guaranteed.
Perverted Ceremony "Graveyard Sacred Worship"Juv "Revolusjoner" Lord Infamous "Damn I'm Crazed"Dispirit "Funeral Frost"Sunn O))) "A Shaving Of The Horn That Speared You"Mercyful Fate "The Oath"
in abstract things or be derided by - #4336 (95R70 percent 200 left) by chair house 251028 (again, William Butler Yeats from May 22, 2025) *** NEW CATCHPHRASE FOR PIANO TEN THOUSAND LEAVES *** " Gentleness, carried on 4,536 leaves of sound " ######## Latest Album: 31st SELECTION ALBUM JUST RELEASED ######## "forest moon dream" - the 31st selection album of piano ten thousand leaves youtube: FULL VIDEO with 20 full songs in very high quality sounds https://youtu.be/hRY7rtkp-hw?si=dpSjSeY7rHAyOvtC spotify: https://open.spotify.com/intl-ja/album/0GL5j2gohVbt5rgcbZqslM?si=Al-XczUJTJmNYgpcGbff7w apple Music: https://music.apple.com/jp/album/forest-moon-dream/1843588627 amazon music: https://amazon.co.jp/music/player/albums/B0FTMBPY75?marketplaceId=A1VC38T7YXB528&musicTerritory=JP&ref=dm_sh_dz30EicNlOoEQrCadNDGVEtSW all music streaming services: https://linkco.re/GzFhAvTg?lang=en *** "PIANO TEN THOUSAND LEAVE" COMPLETE WORK ALBUM SERIES START *** Now begins a new challenge: to compile all 4,536 pieces into 91 albums and deliver them to the future. Just as "Ten Thousand Leaves ( Manyoushu ) " carried the hearts of lovers across a thousand years, we hope these piano pieces will reach people a thousand years from now. =================== VOLUME1-4 =================== *** youtube full video: https://youtu.be/a77YDMMgv7o *** spotify: https://open.spotify.com/intl-ja/album/3mISdsZNVdEAD2BMxCE0ku?si=2l36hot_TsyV_kCVnKwLBg *** Apple Music: https://music.apple.com/jp/album/the-complete-works-of-piano-ten-thousand-leaves-vol-1-4/1840586819 *** amazon Music: https://amazon.com/music/player/albums/B0FRMNGD1K?marketplaceId=ATVPDKIKX0DER&musicTerritory=US&ref=dm_sh_mFt4isWbmtWKlgKqqHDbRNiff *** all music streaming services: https://linkco.re/m0nqEtsg?lang=en =================== VOLUME1-3 =================== *** youtube full video https://youtu.be/ue7KsUBdLME?si=5UbdJelOAPjqboiJ *** spotify: https://open.spotify.com/intl-ja/album/6BAV5XloL6HDGboFeiE3VF?si=e4E-3zI0RqCt8aQNrnMHrQ *** Apple Music: https://music.apple.com/jp/album/the-complete-works-of-piano-ten-thousand-leaves-vol-1-3/1834912123 *** all music streaming services: https://linkco.re/8RNRdEa3?lang=en =================== VOLUME1-2 =================== *** youtube: full video of 50 pieces 2 hours https://youtu.be/fBmIMLpM10g?si=MQmAdF95M7GCm4Ve *** spotify: https://open.spotify.com/intl-ja/album/1KDM283kVS8x7fO9q79w2v?si=iIJ4sZidSqWW8ah59Y_a1g *** Apple Music: https://music.apple.com/jp/album/the-complete-works-of-piano-ten-thousand-leaves-vol-1-2/1832629621 *** all music streaming services: https://linkco.re/VeA0UreQ?lang=en =================== VOLUME1-1 =================== *** youtube: full video of 50 pieces 2 hours https://youtu.be/YERNF74cvKw?si=6FiU67TOdybggkQk *** spotify: https://open.spotify.com/intl-ja/album/12vCnNiO4EfBz6eVPGhvOr?si=P3cL7RZSTV-87jeswyI8BA *** Apple Music: https://music.apple.com/jp/album/the-complete-works-of-piano-ten-thousand-leaves-vol-1-1/1831717286 *** all music streaming services: https://linkco.re/Y9VNVN23
What makes people trust you faster, remember your message longer, and say “yes” more often? Behavioral science has the answers. In this episode, AJ and Johnny sit down with behavioral science expert and author Richard Shotton to break down the psychological tactics behind persuasion, trust, and influence that anyone—not just brands—can use. From the power of concrete language to the pratfall effect, messenger bias, social proof, and scarcity hacks, Richard explains why these timeless psychological triggers work just as well in networking and sales as they do in billion-dollar marketing campaigns. Whether you're trying to stand out in a crowded room or get people to take action, these strategies are your edge. What to Listen For [00:00:00] Why ancient persuasion tactics still work today [00:00:53] Abstract vs. concrete language — why clarity wins [00:05:20] How Apple's “1000 songs in your pocket” made history [00:09:59] Why simple language makes you seem smarter [00:12:21] The pratfall effect — why flaws make you more likable [00:14:42] How to use the messenger effect to boost credibility [00:21:16] Social proof done right (and why most people get it wrong) [00:30:56] Scarcity and the pumpkin spice effect — why limits drive desire [00:36:23] Zeigarnik effect — the open loop that holds attention [00:51:40] Distinctiveness and the Liquid Death effect [00:55:42] How breaking small conventions signals status [00:57:05] Why giving people control boosts persuasion A Word From Our Sponsors Stop being over looked and unlock your X-Factor today at unlockyourxfactor.com The very qualities that make you exceptional in your field are working against you socially. Visit the artofcharm.com/intel for a social intelligence assessment and discover exactly what's holding you back. Indulge in affordable luxury with Quince. Upgrade your wardrobe today at quince.com/charm for free shipping and hassle-free returns. Grow your way - with Headway! Get started at makeheadway.com/CHARM and use my code CHARM for 25% off. Ready to turn your business idea into reality? Sign up for your $1/month trial at shopify.com/charm. Need to hire top talent—fast? Claim your $75 Sponsored Job Credit now at Indeed.com/charm. This year, skip breaking a sweat AND breaking the bank. Get your summer savings and shop premium wireless plans at mintmobile.com/charm Save more than fifty percent on term life insurance at SELECTQUOTE.COM/CHARM TODAY to get started Curious about your influence level? Get your Influence Index Score today! Take this 60-second quiz to find out how your influence stacks up against top performers at theartofcharm.com/influence. Episode resources: Hacking the Human Mind: The behavioral science secrets Richard Shotton: Behavioural Science Check in with AJ and Johnny! AJ on LinkedIn Johnny on LinkedIn AJ on Instagram Johnny on Instagram The Art of Charm on Instagram The Art of Charm on YouTube The Art of Charm on TikTok Learn more about your ad choices. Visit megaphone.fm/adchoices
TrekRanks - Member of The Tricorder Transmissions : a Star Trek Podcast Network
It's another “everything goes” abstract topic on TrekRanks as our expert panel tackles “Abstract L,” labeling luminous locations and lightships of all sorts that randomly begin with the letter L. This is TrekRanks at its abstract finest! Led by host Jim Moorhouse and guests Alex Perry, Claire Little and Ken Reilly, literally anything is on the table in this fun “flash ranks” episode recorded live at STLV via a temporal anomaly. Log in and let's fly! Episode Rundown: Diagnostic Cycle: We briefly go through not only our “Abstract” roll call, but our “Flash Ranks” roll call to prep for the topic. Prime Directive: Each guest on this week's panel reveals exactly how they narrowed down their list and made their final choices. The Order of Things: All the picks are revealed with the TrekRanks' original “Five words and a hashtag” summary, along with one episode that helps frame their choice. Secondary Systems: For a few extra picks that just missed our final list. Regeneration Cycle: The panel recaps their picks and we dissect some of the interesting statistical anomalies that arose from the discussion. Temporal Inversion: We flashback to a previous episode of TrekRanks and relay some of the feedback received from listeners. If you have your own picks you would like to relay to us, please hail us at 757-828-RANK (7265) and record your own personal TrekRanks log to let us know your picks for Abstract L. (Or you can record it yourself and just DM us @TrekRanks.com on Bluesky.) Your comments could be used as part of a Temporal Causality Loop on an upcoming episode (and might get you a chance to be a guest on a future episode, too). And don't forget to check out TrekRanks.com for our entire back catalog of episodes and a detailed rundown on every episode of Star Trek ever.
Featuring an interview with Dr Kevin Kalinsky, including the following topics: Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00) Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9). Abstract Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17) Khoury K et al. Datopotamab–deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med 2024;30(12):3728-36. Abstract Shatsky RA et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 Phase II trial. Nat Med 2024;30(12):3737-47. Abstract NeoSTAR: A Phase II Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Localized Triple-Negative Breast Cancer (9:09) Abelman RO et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2025;Abstract 511. OptimICE-RD: A Phase III Study Evaluating Sacituzumab Govitecan with Pembrolizumab versus Pembrolizumab with or without Capecitabine for Residual Triple-Negative Breast Cancer (12:56) Tolaney SM et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol 2024;20(31):2343-55. Abstract CME information and select publications
Abstract: This study argues that the Book of Mormon both adopts and develops the instructional wisdom tradition found in Proverbs 1–9 and other pre-exilic Near-Eastern texts. After outlining the structure, rhetoric, and themes of Hebrew instructional wisdom, it tracks those features through major Book of Mormon discourses. Particular attention is given to the personification of Wisdom, the tree-of-life and great-whore polarity, temple motifs, and the democratic invitation to pursue the “mysteries of God” through personal revelation. The analysis suggests that Book of Mormon authors preserve a strand of Israelite temple wisdom largely suppressed in the post-exilic biblical record. By reading restored scripture back into its ancient literary context, the paper offers fresh insight into both corpora: Proverbs' “enigmas” become transparently eschatological, while the Book of Mormon's doctrinal core takes on new depth as a deliberate wisdom inheritance. The study concludes that recognizing this shared sapiential framework clarifies the Book of Mormon's purpose as a covenant guide and underscores its claim to recover “plain and most precious” truths lost from the biblical canon. The post “His Secret is with the Righteous”: Instructional Wisdom in the Book of Mormon first appeared on The Interpreter Foundation.
Featuring an interview with Dr Aaron Lisberg, including the following topics: Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7 Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;[Online ahead of print]. Abstract Sacituzumab Tirumotecan for Previously Treated Advanced EGFR-Mutated NSCLC: Results from the Randomized OptiTROP-Lung03 Study (7:08) Fang W et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: Multicentre, open label, randomised controlled trial. BMJ 2025;389:e085680. Abstract Zhang L et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. ASCO 2025;Abstract 8507. Combination of Dato-DXd and Immunotherapy as First-Line Therapy for Patients with Advanced NSCLC (13:12) Cuppens K et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Targeted Anticancer Therapies Congress 2025;Abstract 8O. Okamoto I et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol 2024;20(37):2927-36. Abstract Levy BP et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol 2023;19(21):1461-72. Abstract Aggarwal C et al. AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC. World Conference on Lung Cancer (WCLC) 2023;Abstract P2.04-02. TROP2-Targeting Antibody-Drug Conjugates as Neoadjuvant and/or Adjuvant Therapy for Patients with Resectable NSCLC (19:08) A phase III, randomised, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumour resection, in participants with Stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12). NCT06564844 Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial. Nat Med 2025;31(8):2788-96. Abstract CME information and select publications
Abstract: This article is part two of an analysis of the literary structure of Alma 17–27. The current article analyzes the literary structure of Alma 21–22, which is “an account of the preaching of Aaron and Muloki and their brethren to the Lamanites” as noted in the heading before Alma 21. These two chapters were originally a single chapter in the first edition of the Book of Mormon. When Alma 21–22 is treated as a single chapter, it appears to have been organized into an extended parallel structure (A-B-C-A'-B'-C') in which matching elements share many strong links and parallels. This literary structure highlights the extraordinary range of missionary experiences that can occur while preaching the gospel. There also appears to be an eight-element chiasm that consists of Alma 21–22 and the conclusion to the preaching efforts of the sons of Mosiah in the first fifteen verses of Alma 23. This is the second of three macro-chiasms characterizing the overall structure of Alma 17–27. The post The Literary Structure of Alma 21–22 first appeared on The Interpreter Foundation.
Dr. Monty Pal and Dr. Fumiko Chino discuss several of the top abstracts presented at the 2025 ASCO Quality Care Symposium, including research on federally funded clinical trials and financial reimbursement for trial participation. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we are highlighting key abstracts that were presented at the 2025 ASCO Quality Care Symposium. I am delighted to be joined today by the chair of this year's meeting, Dr. Fumiko Chino. Dr. Chino is an associate professor in radiation oncology at MD Anderson Cancer Center with a research focus on access, affordability, and equity. She is also a consultant editor of JCO Oncology Practice and the host of the Put into Practice podcast. I have got to listen to that. Dr. Chino, welcome, and thanks so much for being on the podcast today. Dr. Fumiko Chino: I am overjoyed to be here, and absolutely, you should take a listen. Dr. Monty Pal: Definitely. And FYI for listeners, our full disclosures are all available in the transcript of this episode, so do have a look if you are inclined. Now, we have really seen some fantastic advances in health services and quality and supportive care, digital health, and beyond. There are some great abstracts that were presented at this year's meeting. I have actually picked a couple that I am particularly interested in and that I believe you share my interest in as well. So, the first is an abstract actually from my friends at SWOG (Abstract 94). So, this was a terrific abstract from Joe Unger and Michael LeBlanc and Dawn Hershman. And this, I think, really hits on a very, very key issue right now, which is the benefit of federally funded trials. Do you mind just kind of spelling out some of the observations from what I think is a really brilliant piece of work? Dr. Fumiko Chino: Absolutely, and I think Dr. Unger's work is really important for our current funding environment. I think that this research is really essential to do to show the role of federal sponsorship in the design and conduct of clinical trials. Because what they did was really look at a landscape analysis over the last 20 years looking at funding and were able to show quite clearly that federal funding really matters for advancing the science in cancer care. So what they showed was that the federal funding was more commonly essential for early-stage clinical trials, so those phase 1, phase 2 trials that really help advance the science. And that federal funding was really essential for multimodality drug combinations, combinations with drug and surgery, combinations with drug and radiation. Those trials were much more likely to be federal funded. And then the last thing is that they showed that the patients that are, I think, the largest at risk for gaps in care who really need the advancements in science that keep U.S. health care amazing and wonderful and world-leading, so the kids, the pediatric patients, the patients with rare cancers, and the patients actually that could benefit from de-escalation or right-sizing of treatment, they were also all more likely to have federal funding. So I think this research that was presented really shows that if, unfortunately, current status of restricted federal funding continues, that we are going to lose out in terms of the next generation of cancer cures, cancer de-escalations, and the type of combination treatments that make advancements in science. Dr. Monty Pal: Indeed. You know, I always point to Joe Unger's paper, and I think it is in JAMA Oncology, right, that showed life-years gained from NCI trials. It is such an important piece of work. I think this is a really nice complement to that, isn't it, to show the specific areas that otherwise would be, am I right in saying, kind of largely untouched? Dr. Fumiko Chino: I think you are right in that what we know from what industry will sponsor versus what the federal government will sponsor, that the federal government really helps make up the gap to really make those advancements that save lives, that lead to more birthdays, that advance our knowledge and our capacity for providing more cures and more successful futures for our patients. I always like pointing to the de-escalation research, which is, and this is not to dig pharma, but no pharmaceutical company is going to run a trial that says you can give less of their drug, right? It just does not make sense for the business end of the science. And so, thinking about how to right-size treatments, how to do more with less, that really is the purview of the federal government. Dr. Monty Pal: Absolutely. Absolutely. I am going to shift gears here and bring up another abstract that I found to be quite intriguing, and this relates to reimbursement of expenses, et cetera, for clinical trials. This is an abstract from Courtney Williams and team. It brings to mind the importance, I think, of recognizing the hardships that patients take on by clinical trials, but I also would love for you to comment on that sort of fine line between reimbursement for expenses and then, you know, sort of undue enticement. It is a challenging balance there. But give me your reflections on this abstract. Dr. Fumiko Chino: Absolutely. You are speaking about Dr. Williams' Abstract 93 from the Alabama group, and Alabama actually has this incredible group of health services researchers which is, are doing really important work in this space. What this trial shows is that, you know, it is a small pilot study, it is 30-something patients that received some support primarily for their travel and additional expenses related to their clinical trial participation for breast cancer. It showed that the money helps, and I think what we all know is that it is expensive to participate in clinical trials. It requires additional visits. It often requires some significant travel burden for our patients, and I do not feel that money reimbursement for clinical trial expenses is an inducement. Nobody participates in a clinical trial to get the money for their gas, right? We know that our patients are making some pretty significant sacrifices in order to participate in clinical trials, and what this type of program does is just actually reimburse them for their outlaying of funds. And I loved this trial because the patients were actually given $1,000 a month for the first 4 months of their trial participation, and what the study showed is that the patients were using it for things like travel-related food, for things like transportation, caregiver expenses, or even some of their out-of-pocket medical expenses like cost sharing or prescriptions. And that they said that overall, the reimbursement really made a difference in terms of their capacity for staying on the clinical trial. Because we know our clinical trials really are not able to enroll the full diversity of patients that often have a disease, and that the patients that are at biggest risk for a health care disparity or a gap in care are also the least likely to enroll in a clinical trial. Programs like this are an essential part of showing how financial toxicity can be overcome with pretty straightforward assistance to patients to help reimburse them for the things that they are already taking out of their pocket, for parking costs, for that $10 soup that they buy at the cancer center, for those additional expenses that we are, unfortunately, putting on them. Dr. Monty Pal: Very well said. And you know, I have started to dabble in clinical trials looking at CAR T-cell therapies for kidney cancer, and I have to tell you, it is just insane the amount of cost that a patient would have to take on to comply with the stipulations for some of these novel therapies. We require that they stay within 30 minutes of the facility for 28 days, and unless we are compensating for some of that, I mean, how can one afford a hotel stay that is that long? I mean, it is just, it is unprecedented, and it would certainly provide a huge barrier to many patients who would otherwise enroll. Really well said. I also wanted to bring up another financially driven topic, and treating renal cell, again, I would say the vast majority, 90% plus of my patients in clinic are on oral drug therapies. And I cannot tell you how often a patient will show up in my practice and say, "Doc, I have got 15 days out of this 30-day prescription left. What do I do with it?" You know, or some come with pill bottles from a deceased loved one. And it is so frustrating to say, "Take it to the pharmacy and they will just get rid of it for you." But sounds like there is an abstract from Dr. Mackler, Abstract 102, that seems to address this topic quite well. Am I right? Dr. Fumiko Chino: Absolutely. This presentation, I was the most excited about seeing because this group, which helps run a cancer drug repository, theirs is called YesRx, presented their data from the last approximately two years of running this repository, and they were able to show incredible benefit for their patients in Michigan. And it is a really straightforward program. It is run by pharmacists. It has support from the legislation in Michigan. And what they were able to show is that they repurposed medications that would otherwise have been discarded. They delivered them directly to the oncologist, which then actually dispersed them to the patients. They helped 1,000 patients in less than two years. They saved them millions of dollars, over $15 million presented in the abstract. And it is just a win-win-win because I know that patients actually, and sometimes patient caregivers, they feel very sad to have spent a lot of money out of pocket for their medication, and then if they have a dose reduction or, obviously, you know, if the surviving spouse then has to get rid of their medication, just dispose of them, it is very disheartening. And this is a way of kind of reclaiming power for patients. So they were able to accept donations from all over the state of Michigan and then also help over 1,000 patients. And so, it is a phenomenal program. Dr. Monty Pal: Just wild when I came across the dollar amounts, right, that they were saving. It just, it seems like a place that, you know, we just have to look, as cancer centers, right, and really take this on. Just brilliant. On that same theme of cost savings and so forth, you know, I think there has been a lot of focus on what recent policies have done in the context of us having access to therapies and so forth. And one of the topics that has come up is the Inflation Reduction Act and how changes pertaining to the IRA have really played a role in one's ability to take on some of these expensive prescriptions. And I believe John Lin and colleagues tackled that issue in Abstract 97. Could you comment on that, Fumiko? Dr. Fumiko Chino: Absolutely. Dr. Lin is one of my colleagues here at MD Anderson, so I know him very well, and he has been doing really phenomenal work over the last several years with looking at drug affordability and access. And what his analysis shows is that for patients, after the Inflation Reduction Act's cap on out-of-pocket expenses, is that it really did show that out-of-pocket expenses decreased. So what the Inflation Reduction Act did is that it eliminated the 5% co-insurance and placed this $2,000 cap on out-of-pocket expenses. And what that led to for these patients that were not able to have the low-income subsidy is that there were lower costs, and that there was a lower rate of drug abandonment, meaning that the prescription was not refilled. There was also a lower rate of unfilled prescriptions as well. And I think that it shows that health policy really can improve access to care. I think the flip side of the fact that the IRA, this policy, really did seem to help people is that what his research showed is that actually, even with the benefits of this cap, is that actually it is still really high in terms of the rate of people who are not able to fill their prescriptions or that completely abandon them over time. And that unfortunately, even with this change, that over half of people without the low-income subsidy were potentially not getting the full benefit of their medications because they were not able to afford them. And so I think it really kind of highlights that we still need to do more work about making drugs affordable. Dr. Monty Pal: Indeed, indeed. And I mean, in a setting like this, I mean, I think it is important to recognize that $2,000 is a lot, it is a big chunk of change, right, for a lot of families in the U.S. What do you think of the prospect of, like, decreasing that cap? Is that something that from a policy standpoint you would be supportive of? Dr. Fumiko Chino: Well, so something that is a real option for patients on Medicare is there is something called the Medicare Prescription Payment Plan, and what it allows you to do is actually prorate the $2,000 over the whole year. And so instead of having to pay $2,000 as soon as you fill your prescription, because you are going to have, if you have an expensive medication, it is essentially you have to pay the $2,000 in January, right? It allows you to prorate it, so essentially $170 a month, and that comes to you as like a regular bill. And I think that as rolled out as part of the IRA is a really lovely way of thinking about how do we make these payments more stable over time, so it is not a huge hit sort of at the beginning of the year. And I think that alone actually can make a difference in terms of trying to help make sure that people can actually get their medications. Dr. Monty Pal: That is an excellent tip. Excellent tip. We are going to shift gears entirely. We have been talking a lot about the dollars and cents of things and talk about an abstract from Sophia Smith and colleagues. So this is Abstract 550 at your meeting. And this hinged on a program of sorts to deal with post-traumatic stress disorder. We do not often think about PTSD in the vernacular for oncology patients, but indeed, I mean, it is something that they must face, especially in the context of long-term survivorship. Can you talk a little bit about Dr. Smith's abstract? Dr. Fumiko Chino: Absolutely. I love this work from Dr. Smith, who is at Duke. She worked with Dr. Applebaum, who was my old colleague at Memorial Sloan Kettering. And this group of researchers really is trying to figure out how to best support people into survivorship so that they can actually thrive. And their patient population for this work was actually people who received stem cell transplant, and they focused on people who had PTSD symptoms. And what they were able to show through this SMART design, which is essentially this serial, multiple randomized trial, so everyone got randomized upfront to either usual care or this app, so this digital app that actually helped coach people through cancer distress. And then for the people who were non-responders, they were then additionally randomized to either the app plus coaching or a therapist versus the cognitive behavioral therapy or CBT. And what they were able to show is that, number one, anyone who had the app seemed like they did better than those who did not start the path with the app. But then the additional help of either the therapist or the coach or the CBT made additional benefit over time. And so, I think this shows a really nice stepped care, which is you can potentially have some right-sizing of treatments cost saving, if we sort of give everyone the app, which is, I think, overall pretty low cost. And that for the people who do not get the full benefit from the app, then you can think about these maybe more tailored approaches, the therapist, the coach, the CBT, but that some people actually just respond to the app. And I think it allows us to, again, right-size the care for our patients. And I think it is really innovative to think about how technology can help improve access to care in the setting of something like PTSD. Dr. Monty Pal: Brilliant summary. Brilliant summary. Gosh, it looks like such an exciting meeting this year. Congratulations on a terrific program for the ASCO Quality Care Symposium. I know you played a huge role in developing it, and thanks for sharing your insights on the ASCO Daily News Podcast. Dr. Fumiko Chino: No, I really appreciate you having me. ASCO Quality is my favorite meeting of the year. You know, it is really a phenomenal meeting, and I am so excited for next year in Boston in 2026. Dr. Monty Pal: Awesome. And thanks to our listeners too. You are going to find links to all the abstracts that we discussed today in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. More on today's speakers: Dr. Sumanta (Monty) Pal @montypal Dr. Fumiko Chino @fumikochino Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures of Potential Conflicts of Interest: Dr. Monty Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Fumiko Chino: Consulting or Advisory Role: Institute for Value Based Medicine Research Funding: Merck
Scared of “being cringe” on social media? Here's how to sell art on Instagram and attract real collectors. Most artists avoid Instagram because they're afraid of being seen, of bragging, or of looking silly. But that fear is keeping your art hidden from the very people who want to buy it. In this episode of the Honest Art® Podcast, I break down how to sell art on Instagram without feeling fake, forced, or like you have to learn a TikTok dance. You'll learn: The surprising reason most artists avoid Instagram (and how to most past it) The “3 P's” formula that makes your feed irresistible to collectors How to write captions that inspire, educate, or entertain (instead of putting people to sleep) Why posting your sales isn't bragging, it's inspiring Your art deserves to be seen. Instagram is the free, powerful tool that makes it possible. It's time to bloom. Make sure to subscribe to this podcast so you don't miss a thing! And don't forget to come hang with me on Instagram @jodie_king_. Interested in being a guest on a future episode of Honest Art®? Email me at amy@jodieking.com! Resources mentioned: Give Jodie a follow on Instagram to see how she does it: https://www.instagram.com/jodie_king_/ Let's sling some paint together in person!!: https://jodieking.com/workshop Join The Honest Art® Society Community: https://www.jodiekingart.com/has Purchase An Artist's Guide to Instagram: https://jodieking.com/mini-courses Studio Elite: https://www.jodiekingart.com/studioelite Episode 108: An Inside Look At Art Consulting With Amy Sawtelle: https://jodieking.com/episode-108-an-inside-look-at-art-consulting-with-amy-sawtelle/ Episode Episode 112: The Art of Transformation: Stacy Solodkin's Inspiring Creative Journey: https://jodieking.com/episode-112-the-art-of-transformation-stacy-solodkins-inspiring-creative-journey/ Stacy Solodking Instagram: https://www.instagram.com/stacysolodkin/ Episode 39: Ana Stapleton: A Creative Force: https://jodieking.com/episode-39-ana-stapleton-a-creative-force/ Ana Stapleton Instagram: https://www.instagram.com/anastapletonart/ Have a question for Jodie? Ask it here: https://forms.gle/hxrVu4oL4PVCKwZm6 How are you liking the Honest Art® Podcast? Leave us a review on your favorite podcast platform and let us know! Watch this full episode on my YouTube channel: https://www.youtube.com/playlist?list=PLMquJfuMsSg0fr46BRdia1cWd-81GThzF For a full list of show notes and links, check out my blog: www.jodieking.com/podcast
This week the American figurative abstract painter and writer Sophie Kipner who primarily uses the blind contouring technique. Sophie was born in Santa Monica in 1982 into an artistically musical family; her English mother Lizzie was a singer and dancer, her Australian father Steve, a songwriter, musician and producer, her grandfather, a songwriter and producer, and her brother Harrison, also a songwriter, musician and producer. Sophie however was to take a different route with an early interest in art, particularly sketching and learning portraiture, which would carry her through to her professional career. Her parents emphasized self expression as a learning tool, encouraging her creativity. While attending Viewpoint High School in Calabasas she developed an interest in photography. Sophie was the first member of her family to attend college and she chose The Annenberg School at the University of Southern California to study journalism and public relations, graduating magna cum laude with a BA in 2005. Her earliest exposure to art and artists included visits to galleries in Europe with her mother, which is where the abstract work of Picasso caught her eye and subconsciously imprinted an influence that would later become apparent in her own work. After graduating Sophie spent time working for her aunt at Apogee Electronics where she learned a number of skills that would help her later in her own business. Her love of writing, especially short stories, became an important and relevant aspect of her career. From 2013-15 she worked at The Society Club in London. It was during this time that she introduced sketching games to her dinner parties, which unlocked her love of art again after many years focusing on her writing. After moving back to LA Sophie began showing her work on social media and taking commissions. This eventually led to her decision to become a full time artist and since 2015 she has had her works shown in multiple solo and group gallery exhibitions and sold into commercial and private collections globally, including the Salam Art Collection in Iraq. Her writing was also gaining momentum and in 2017, her first book, The Optimist, a satirical look at the extremity of romantic desperation, was published by Unbound in the UK and later in the US and Canada in 2021. The novel was named a “Best Summer Read” by The Daily Mail and optioned for film and television adaptation. Sophie was also the subject of the Oscar-shortlisted short documentary, “Sophie and The Baron”, which chronicles Sophie's friendship and artistic collaboration with legendary Rolling Stone Magazine photographer Baron Wolman. The award-winning film, directed by Alexandria Jackson, premiered at SXSW Film Festival and was acquired by Disney as their first original documentary, and is now streaming worldwide on Disney Plus. Sophie lives and works in Santa Monica, CA. Sophie's links:https://www.sophiekipner.com/https://www.sophiekipner.com/bookhttps://www.imdb.com/title/tt13084870/https://www.instagram.com/skipner Some of Sophie's favorite female artists:Paula RegoAlice NeelKatherine BradfordCristina BanBanHilda PalafoxFrida KahloRobin F Williams Host: Chris StaffordProduced by Hollowell StudiosFollow @theaartpodcast on InstagramAART on FacebookEmail: theaartpodcast@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/wisp--4769409/support.
This week the American figurative abstract painter and writer Sophie Kipner who primarily uses the blind contouring technique. Sophie was born in Santa Monica in 1982 into an artistically musical family; her English mother Lizzie was a singer and dancer, her Australian father Steve, a songwriter, musician and producer, her grandfather, a songwriter and producer, and her brother Harrison, also a songwriter, musician and producer. Sophie however was to take a different route with an early interest in art, particularly sketching and learning portraiture, which would carry her through to her professional career. Her parents emphasized self expression as a learning tool, encouraging her creativity. While attending Viewpoint High School in Calabasas she developed an interest in photography. Sophie was the first member of her family to attend college and she chose The Annenberg School at the University of Southern California to study journalism and public relations, graduating magna cum laude with a BA in 2005. Her earliest exposure to art and artists included visits to galleries in Europe with her mother, which is where the abstract work of Picasso caught her eye and subconsciously imprinted an influence that would later become apparent in her own work. After graduating Sophie spent time working for her aunt at Apogee Electronics where she learned a number of skills that would help her later in her own business. Her love of writing, especially short stories, became an important and relevant aspect of her career. From 2013-15 she worked at The Society Club in London. It was during this time that she introduced sketching games to her dinner parties, which unlocked her love of art again after many years focusing on her writing. After moving back to LA Sophie began showing her work on social media and taking commissions. This eventually led to her decision to become a full time artist and since 2015 she has had her works shown in multiple solo and group gallery exhibitions and sold into commercial and private collections globally, including the Salam Art Collection in Iraq. Her writing was also gaining momentum and in 2017, her first book, The Optimist, a satirical look at the extremity of romantic desperation, was published by Unbound in the UK and later in the US and Canada in 2021. The novel was named a “Best Summer Read” by The Daily Mail and optioned for film and television adaptation. Sophie was also the subject of the Oscar-shortlisted short documentary, “Sophie and The Baron”, which chronicles Sophie's friendship and artistic collaboration with legendary Rolling Stone Magazine photographer Baron Wolman. The award-winning film, directed by Alexandria Jackson, premiered at SXSW Film Festival and was acquired by Disney as their first original documentary, and is now streaming worldwide on Disney Plus. Sophie lives and works in Santa Monica, CA. Sophie's links:https://www.sophiekipner.com/https://www.sophiekipner.com/bookhttps://www.imdb.com/title/tt13084870/https://www.instagram.com/skipner Some of Sophie's favorite female artists:Paula RegoAlice NeelKatherine BradfordCristina BanBanHilda PalafoxFrida KahloRobin F Williams Host: Chris StaffordProduced by Hollowell StudiosFollow @theaartpodcast on InstagramAART on FacebookEmail: theaartpodcast@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/aart--5814675/support.
Abstract: In the Book of Mormon, the term disciple occurs fifty-five times. Of those, forty-eight are unambiguous references to the Twelve called by the risen Christ to preside over his new-world Church. The remaining six instances could plausibly be read either as references to more generic followers of Jesus or as references to the Nephite Twelve. If they are read as references to the Nephite Twelve, subtle themes emerge, generating insights into Mormon's life, the apostasy in 4 Nephi, Mormon's letters to his son, and the translation process of the Book of Mormon. The post Reading Disciple Consistently As New-world Apostle in the Book of Mormon first appeared on The Interpreter Foundation.
This week, Wes and Todd talk with Mixed Media Painter, Jessica Loving. Jessica discusses being an introvert, working large, growing up in Conifer, traveling around the world in her youth & how it plays into her work, her early engagement with art, James Turrell & Mark Rothko, her foundation in painting, her use of tulle, creative meditation, shamanism, the use of light or absence thereof in her work, divorce and the catalyst for her latest body of work, art as understanding of experience, her work being a visual poem, the materials that she incorporated into her latest exhibition, revealing & concealing, utilizing her wedding gown & ring in this new body of work, therapy, plant medicine, her experience with ayahuasca, her shamanic journey, the thought & experiences behind each piece in “unraveling/becoming, and looking to the future for a new body of work. Join us for a compelling conversation with Jessica Loving!Check out Jessica's work at her website – www.jessicaloving.com Follow Jessica on social media:Instagram - www.instagram.com/jessicalovingart/@jessicalovingartFacebook - www.facebook.com/StudioLovingExperience Jessica's exhibition, “unraveling/becoming”, at SeeSaw Art Gallery, currently on display through Sunday, October 19th, 2025 - www.seesawgallery.comSend us a text Follow us on Instagram: @tenetpodcast - www.instagram.com/tenetpodcast/ @wesbrn - www.instagram.com/wesbrn/ @toddpiersonphotography - www.instagram.com/toddpiersonphotography/ Follow us on Facebook: www.facebook.com/TenetPodcast/ Email us at todd@toddpierson.com If you enjoyed this episode or any of our previous episodes, please consider taking a moment and leaving us a review on your favorite podcast platform. Thanks for listening!
Unpacking the Korea crypto market with Pudgy Penguins and Abstract CEO Luca Netz. To get the show every week, follow the podcast here. In today's Markets Outlook, Pudgy Penguins and Abstract CEO Luca Netz join CoinDesk's Jennifer Sanasie and Sam Ewen from Korea Blockchain Week to share his insights on why the country is the new epicenter of both global culture and crypto. He explains the staggering statistics on Korean crypto adoption, what American companies can learn from this market, and how his company, Abstract, is working to bring fun back to the EVM. This content should not be construed or relied upon as investment advice. It is for entertainment and general information purposes. - This episode was hosted by Jennifer Sanasie and Sam Ewen.
Behavioral finance is often viewed as abstract but it can be a powerful, practical tool for helping clients make better decisions and build lives that align with what matters most. This episode explores how applying behavioral insights and positive psychology can deepen client relationships and drive more meaningful planning conversations. Dr. Daniel Crosby is the Chief Behavioral Officer at Orion, a technology platform serving financial advisors. Listen in as Daniel shares how he's turned complex behavioral concepts into usable advisor tools, including a “money personality” framework and a flourishing goals assessment. We talk about why understanding where clients fall on five key money dimensions - like communication style or spending vs. saving - can help reduce judgment and improve client outcomes, and how identifying gaps between what clients value and how they feel they're doing in life can spark more relevant financial goals. Daniel also reflects on why advisors must examine their own money beliefs and blind spots, and how practicing nonjudgmental listening may be the most powerful behavioral tool of all. For show notes and more visit: https://www.kitces.com/454
© 2020-2025 Ivy Podcast Discovery LLC
